The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Open accessAbstract
Previous findings have suggested that class IIa histone deacetylases (HDACs) (HDAC4, -5, -7, and -9) are inactive on acetylated substrates, thus differing from class I and IIb enzymes. Here, we present evidence supporting this view and demonstrate that class IIa HDACs are very inefficient enzymes on standard substrates. We identified HDAC inhibitors unable to bind recombinant human HDAC4 while showing inhibition in a typical HDAC4 enzymatic assay, suggesting that the observed activity rather reflects the involvement of endogenous copurified class I HDACs. Moreover, an HDAC4 catalytic domain purified from bacteria was 1,000-fold less active than class I HDACs on standard substrates. A catalytic Tyr is conserved in all HDACs except for vertebrate class IIa enzymes where it is replaced by His. Given the high structural conservation of HDAC active sites, we predicted the class IIa His-Nε2 to be too far away to functionally substitute the class I Tyr-OH in catalysis. Consistently, a Tyr-to-His mutation in class I HDACs severely reduced their activity. More importantly, a His-976-Tyr mutation in HDAC4 produced an enzyme with a catalytic efficiency 1,000-fold higher than WT, and this “gain of function phenotype” could be extended to HDAC5 and -7. We also identified trifluoroacetyl-lysine as a class IIa-specific substrate in vitro . Hence, vertebrate class IIa HDACs may have evolved to maintain low basal activities on acetyl-lysines and to efficiently process restricted sets of specific, still undiscovered natural substrates.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Vertebrate class IIa HDACs carry a conserved active-site Tyr-to-His substitution that makes them very inefficient on canonical acetyl-lysine substrates, with most deacetylase activity in class IIa complexes coming from associated class I HDACs. A single His-to-Tyr mutation restores high catalytic activity, and trifluoroacetyl-lysine is identified as a class IIa-specific substrate in vitro.
Key findings
- The catalytic Tyr conserved in other HDACs is replaced by His in vertebrate class IIa HDACs; mutating HDAC3 Y298 to H abolished activity on pepH4-AcK16, and HDAC1 Y303H reduced activity 5- to 8-fold.
- HDAC4 catalytic domain purified from E. coli had measurable activity but was at least 1,000-fold lower than class I HDACs and 100-fold lower than the HDAC4-FLAG complex; it was inactive on pepH4-AcK16.
- HDAC4 H976Y produced a gain-of-function phenotype: >20-fold increased activity for HDAC4-FLAG and >1,000-fold for HDAC4-CD, reaching levels comparable to class I enzymes; similar effects were seen for HDAC5 H1006Y and HDAC7 H843Y.
- Trifluoroacetyl-lysine was identified as a class IIa-specific substrate in vitro, processed by HDAC4 full-length and catalytic domain and by three class IIa enzymes, but poorly by class I and class IIb HDACs.
Methods
- HDAC4 was used as a representative class IIa model with four approaches: HDAC inhibitor binding/inhibition comparison, functional analysis of purified HDAC4 catalytic domain expressed in E. coli, structure-guided mutagenesis, and substrate screening.
- Deacetylase assays used 3[H]acetyl-core histones purified from HeLa cells or fluorescent pepH4-AcK16, plus a commercial Fluor de Lys assay; HDAC inhibitor activities were measured by preincubation with enzymes before substrate addition.
- Binding was assessed by pull-down with biotinylated LAQ824/apicidin derivatives and by UV cross-linking; sequence analysis used CLUSTALW/Genedoc and structural analysis used bacterial class II homolog PDB 1ZZ1.
Limitations
- Stated: the lack of isotype/class-specific HDAC inhibitors limits distinguishing class IIa intrinsic activity from associated class I HDACs; attempts to obtain active recombinant class IIa HDACs in heterologous systems were unsuccessful, and it remains unknown whether this reflects missing cofactors or endogenous class I enzymes.
- Stated: the precise role of HDAC4 catalytic activity in atypical biological contexts remains to be elucidated, and identification of additional biological activities/substrates dependent on class IIa H-associated activity requires further work.
- Evident from the text: the study relies heavily on in vitro assays and ectopically expressed proteins, and no natural physiological class IIa-specific substrate is identified; the proposed specialized vertebrate class IIa activity is therefore inferred from synthetic substrate data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
32 Own result · 24 Own interpretation · 10 Not checked yet · 2 Own method · 2 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, we have identified trif luoroacetyl-lysine as a class IIa-specific substrate in vitro.”
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the Y298H substitution in HDAC3 did not affect its association with N-CoR DAD (Fig. 2B), suggesting that the integrity of the catalytic domain was preserved.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, replacement of Y with H produced a loss-of-function phenotype as severe as that caused by replacement with F (SI Fig. 8A).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As predicted, replacing the active site Y with H was sufficient to abolish the enzymatic activity on a histone H4-derived peptide containing a single acetyl-lysine (pepH4-AcK16) (Fig. 2A).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in SI Fig. 8C, the mutation actually reduced HDAC1 deacetylase activity 5-to 8-fold.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Class IIa HDACs possess a weak but measurable intrinsic capability of hydrolyzing acetyl-lysines in vitro.”
- Also stated in: § HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs. · plain
“HDAC4-CD showed a measurable deacetylase activity both in the histone-based (Fig. 4B) and the commercial (SI Fig. 10A) HDAC assays.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, catalytic activity toward canonical HDAC substrates could be restored by a single H-to-Y substitution in the active site.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in SI Fig. 8E, mutation into F did not alter the activity of the purified HDAC4 complex on pepH4-AcK16.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Class IIa HDACs with the H Mutated into F Are Not Impaired in Their
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The H976Y mutation did not enhance HDAC4 transcriptional inhibitory activity, despite its clear effect on the enzymatic activity in vitro (SI Fig. 12 A).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When challenged in activity assays, HDAC4-CD showed a measurable deacetylase activity both in the histone-based (Fig. 4B) and the commercial (SI Fig. 10A) HDAC assays.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 23
- The quote only partly states this claim. 1
- Probably not a substantial claim. 4
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the vertebrate class IIa HDACs, the catalytic Y is replaced by an H, a conservative substitution, whereas other functional residues are virtually always conserved (SI Fig. 7).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Sequence and Structure Analysis Indicates that Vertebrate Class IIa
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This protein was efficiently pulled-down on biotinylated LAQ824 beads (Fig. 4A), suggesting that the structural integrity of the catalytic domain was preserved in the recombinant truncated mutant.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, LAQ824 and apicidin had similar effects in this assay in contrast to the different inhibitory potencies and binding affinities shown in vitro.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Again Y mutants exhibited strongly increased activity compared with WT and, like the HDAC4 mutant, could be inhibited by LAQ824 but were resistant to apicidin.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pull-down was significantly reduced by preincubation with an excess of free LAQ824, whereas apicidin and MS275 did not show competition, thus confirming and directly validating the results obtained with ectopic HDAC4-FLAG.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Different than WT HDAC4-FLAG, Y mutants were sensitive only to the inhibitory effect of LAQ824, but they were highly resistant to inhibition by compounds belonging to different chemical classes (MS-275, apicidin, and its open derivative), all of which are active on class I HDACs (data not shown).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, HDAC4-CD was completely inactive on pepH4-AcK16 and on a number of acetylated peptides grafted from nonhistonic HDAC substrates (data not shown).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Having ascertained that class IIa HDACs are not proficient enzymes on acetyl-lysines, we sought alternative in vitro substrates.”
- Also stated in: § HDAC4 Compound Binding Assays. · boosted
“Here, we present evidence supporting this view and demonstrate that class IIa HDACs are very inefficient enzymes on standard substrates.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Identification of a Class IIa-Specific Substrate.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § HDAC4 Compound Binding Assays. · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, this compound was actively and specifically processed by three different class IIa enzymes, whereas it was a poor substrate for both class I and class IIb HDACs (Fig. 6).”
- Also stated in: § Discussion · plain
“We have identified a class IIa-specific synthetic substrate, trifluoroacetyl-lysine.”
- Also stated in: § HDAC4 Compound Binding Assays. · plain
“Trifluoroacetyl-lysine is a class IIa-specific substrate in vitro.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Identification of a Class IIa-Specific Substrate.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified HDAC inhibitors unable to bind recombinant human HDAC4 while showing inhibition in a typical HDAC4 enzymatic assay, suggesting that the observed activity rather reflects the involvement of endogenous copurified class I HDACs.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Compound Binding Assays.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, ascidian class IIa sequences also lack one of the conserved Zn ligands, a D is replaced by an S (SI Fig. 7).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In class IIa HDACs, three different residues (Y, H, and F) are observed at this position and, given the particular structural context, it is unlikely that for each residue a concomitant conformational change would occur.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Sequence and Structure Analysis Indicates that Vertebrate Class IIa
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This experimental evidence also proved the HDAC4 catalytic domain to be properly folded under our experimental conditions, because a single amino acid substitution was sufficient to confer high enzymatic activity.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the HDAC4-CD mutant showed an inhibition profile identical to that of the full-length HDAC4-FLAG mutant, suggesting that the observed selectivity is directly related to the catalytic domain and does not depend on additional N-terminal regions.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these results demonstrate that HDAC4 intrinsic catalytic activity is low on canonical acetylated substrates and does not contribute significantly to the overall activity observed in purified ectopic HDAC4 complexes.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“All class IIa members expressed in mammalian cells are known to recruit class I HDACs, which possess high deacetylase activities both in vitro and in cells (18)(19)(20).”
What the sources say
- Not checked yetcites (18)(19)(20)
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Remarkably, compounds that did not inhibit the H976Ysubstituted enzymes were those that did not bind WT HDAC4, thus implying that the mutant proteins retain the WT selectivity of interactions.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It is well documented that class IIa HDACs are potent and selective transcriptional repressors (4).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
What the sources say
- Not checked yetcites [4] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This finding was confirmed both in the isolated catalytic domain expressed in a prokaryotic system as well as for the full-length enzymes expressed in mammalian cells, including HDAC5 and -7.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The emergent theme predicts class IIa HDACs with intrinsically different catalytic activities for the two groups: (i) canonical HDAC activity in invertebrates and (ii) a more specialized enzymatic activity in vertebrates.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: The catalytic mechanism of HDACs is conserved across the enzymes and species considered.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mechanistically, the presence of the trifluoro group should destabilize the amide bond and thus favor the reaction even in the absence of transition-state stabilization, as postulated for the His-containing class IIa HDACs.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: The catalytic mechanism of HDACs is conserved across the enzymes and species considered.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean values of at least two independent assays are reported.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Methods Sequence Analysis and Modeling.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our MEF2 reporter gene data are in agreement with these findings, excluding HDAC4 catalytic activity for being responsible for transcriptional repression and pointing to the involvement of class I enzymes that are equally sensitive to the inhibition by both LAQ824 and apicidin.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, our data also imply that class IIa HDACs should be considered a distinct class of therapeutic targets, concerning both their natural substrates and selective mechanisms of inhibition.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: Vertebrate class IIa HDACs have natural substrates that are not canonical acetyl-lysines.
- Rests on an assumption: In vitro substrate specificity of class IIa HDACs reflects their in vivo biological function.
None of the sources cited for this claim have been checked yet.
In the paper
“More recently, it has been shown that both Sirt1 (28) and HDAC3 (29), and not HDAC4 or -5, efficiently deacetylate MEF2D, thus contributing to MEF2Ddependent transcriptional repression.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The authors state this as an assumption.
The catalytic mechanism of HDACs is conserved across the enzymes and species considered.
“Based on our results, the presence of an F should be incompatible with activity, provided that the catalytic mechanism is conserved.”
The paper relies on this without support.
Vertebrate class IIa HDACs have natural substrates that are not canonical acetyl-lysines.
“Future work will undoubtedly identify these yet unknown physiological substrates and further reveal the already complex biological activities of these enzymes.”
The paper relies on this without support.
In vitro substrate specificity of class IIa HDACs reflects their in vivo biological function.
“our results point to a previously unknown, specific catalytic activity of vertebrate class IIa HDACs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Class IIa enzymes (Lahm et al., 2007) as well as HDAC3 (Madsen and Olsen, 2012a), HDAC8 (Bradner et al., 2010), and HDAC11 (Inks et al., 2012) removed the physiologically non-relevant trifluoroacetamide (Ktfa).”
From Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase (2018) · cites this paper as Lahm et al., 2007
In the citing paper
“In vertebrates, this subfamily is characterized by limited catalytic activity, mainly due to the replacement of a tyrosine (Y) with a histidine (H) residue in the enzymatic pocket (Lahm et al., 2007).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Lahm et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Compound Binding Assays.
“A catalytic Tyr is conserved in all HDACs except for vertebrate class IIa enzymes where it is replaced by His.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
“Yet another residue, F, is instead found in class IIa homologs of the ascidians Ciona intestinalis, Ciona savignyi, and Halocynthia roretzi.”
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Dent, S., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,906
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,856
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,497
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis
Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 805
Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754
Cited by
Sorted by citations
Items 101–200 of 609
FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3
Wang, L., Liu, Y., Han, R., Beier, U. H., Bhatti, T. R., Akimova, T., Greene, M. I., Hiebert, S. W., & Hancock, W. W. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77088 · Cited by 107
An evolving understanding of nuclear receptor coregulator proteins
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0227 · Cited by 111
Chemical and structural biology of protein lysine deacetylases
Yoshida, M., Kudo, N., Kosono, S., & Ito, A. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.019 · Cited by 109
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
Wawruszak, A., Kałafut, J., Okoń, E., Czapiński, J., Hałasa, M., Przybyszewska-Podstawka, A., Miziak, P. A., Okła, K., Rivero‐Müller, A., & Stepulak, A. (2019) · Cancers · doi:10.3390/cancers11020148 · Cited by 102
Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics
Walkinshaw, D. R., & Yang, X. (2008) · Current Oncology · doi:10.3747/co.v15i5.371 · Cited by 104
McGee, S. L., & Hargreaves, M. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.06.002 · Cited by 107
Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
Duong, V., Bret, C., Altucci, L., Mai, A., Duraffourd, C. C., Loubersac, J., Harmand, P.-O., Bonnet, S., Valente, S., Maudelondé, T., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0299 · Cited by 110
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases
JONES, P. G., Altamura, S., Francesco, R. D., Gallinari, P., Lahm, A., Neddermann, P., Rowley, M., Serafini, S., & Steinkühler, C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.025 · Cited by 103
Self-citationProbing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity
Haggarty, S. J., & Tsai, L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.04.009 · Cited by 104
Integrated mechanisms of CaMKII-dependent ventricular remodeling
Kreußer, M. M., & Backs, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00036 · Cited by 98
Thaler, F., & Mercurio, C. (2013) · ChemMedChem · doi:10.1002/cmdc.201300413 · Cited by 99
Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors
Spencer, J., Amin, J., Wang, M., Packham, G., Alwi, S. S. S., Tizzard, G. J., Coles, S. J., Paranal, R. M., Bradner, J. E., & Heightman, T. D. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100295v · Cited by 95
Metabolic reprogramming by class I and II histone deacetylases
Mihaylova, M. M., & Shaw, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.09.003 · Cited by 100
Zhang, Y., Ying, J. B., Hong, J. J., Li, F., Fu, T. T., Yang, F. Y., Zheng, G. X., Yao, X., Lou, Y., Qiu, Y., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00729 · Cited by 95
Wang, H., Yu, N., Chen, D., Lee, K. C. L., Lye, P. L., Chang, J. W. W., Deng, W., Ng, M., Lu, T., Khoo, M. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2003552 · Cited by 93
Chromatin regulation in drug addiction and depression
Renthal, W. R., & Nestler, E. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/wrenthal · Cited by 92
Mathias, R. A., Guise, A. J., & Cristea, I. M. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o114.046565 · Cited by 93
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., Kiss, J., Selt, F., Konrad, C., Lodrini, M., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0201-7 · Cited by 92
Ishii, S., KURASAWA, Y., Wong, J., & Yu‐Lee, L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710140105 · Cited by 95
HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1α, and Hsc70
Luo, L., Martin, S. C., Parkington, J. D., Cadena, S. M., Zhu, J., Ibebunjo, C., Summermatter, S., Londraville, N., Patora‐Komisarska, K., Widler, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.023 · Cited by 93
Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis
Chen, F., Gao, Q., Wei, A., Chen, X., Shi, Y., Wang, H., & Cao, W. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00631-9 · Cited by 93
Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis
Zhou, B., Margariti, A., Zeng, L., & Xu, Q. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr003 · Cited by 89
Patel, V. P., Mazitschek, R., Coleman, B. I., Nguyen, C., Urgaonkar, S., Cortese, J. F., Barker, R. H., Greenberg, E. F., Tang, W., Bradner, J. E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801654y · Cited by 87
Lewandowski, S. L., Janardhan, H. P., & Trivedi, C. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.684753 · Cited by 85
Halsall, J. A., & Turner, B. M. (2016) · BioEssays · doi:10.1002/bies.201600070 · Cited by 87
Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900850t · Cited by 85
Montero, A., Beierle, J. M., Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809508f · Cited by 83
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
Kikuchi, S., Suzuki, R., Ohguchi, H., Yoshida, Y., Lu, D., Cottini, F., Jakubı́ková, J., Bianchi, G., Harada, T., Görgün, G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.83 · Cited by 83
Mechanisms of action of tasquinimod on the tumour microenvironment
Raymond, É., Dalgleish, A. G., Damber, J. ‐., Smith, M. R., & Пили, Р. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2321-8 · Cited by 83
Zhou, Y., Jin, X., Ma, J., Ding, D., Huang, Z., Sheng, H., Yan, Y., Pan, Y., Wei, T., Wang, L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2828 · Cited by 82
HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer
Zhou, Y., Jin, X., Yu, H., Qin, G.-D., Pan, P., Zhao, J.-Y., Chen, T., Liang, X.-Y., Sun, Y., Wang, B., et al. (2022) · Theranostics · doi:10.7150/thno.69444 · Cited by 78
The acetyltransferase HAT1 moderates the NF-κB response by regulating the transcription factor PLZF
Sadler, A. J., Suliman, B. A., Yu, L., Yuan, X., Wang, D., Irving, A. T., Sarvestani, S. T., Banerjee, A., Mansell, A. S., Liu, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7795 · Cited by 82
Mandl–Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F. S., Schmidmaier, R., & Baumann, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08124.x · Cited by 83
Zhuang, Q., Li, W., Benda, C., Huang, Z., Ahmed, T., Liu, P., Guo, X., Ibañez, D. P., Luo, Z., Zhang, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0047-x · Cited by 77
study, D., Zhou, W., He, Y., Rehman, A. U., Kong, Y., Hong, S., Ding, G., Yalamanchili, H. K., Wan, Y., Paul, B., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0311-1 · Cited by 83
HDAC inhibitor therapy in autoimmunity and transplantation
Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y., & Wang, L. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200593 · Cited by 78
The Histone Deacetylase HDAC4 Regulates Long-Term Memory in Drosophila
Fitzsimons, H. L., Schwartz, S., Given, F. M., & Scott, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083903 · Cited by 78
Gaur, V., Connor, T., Sanigorski, A. J., Martin, S. D., Bruce, C. R., Henstridge, D. C., Bond, S. T., McEwen, K. A., Kerr-Bayles, L., Ashton, T. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.005 · Cited by 78
Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches
Li, W., & Sun, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071616 · Cited by 77
Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders
Gupta, R. V., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117278 · Cited by 85
Complex neuroprotective and neurotoxic effects of histone deacetylases
Thomas, E. A., & D’Mello, S. R. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14309 · Cited by 76
Effects of novel HDAC inhibitors on urothelial carcinoma cells
Kaletsch, A., Pinkerneil, M., Hoffmann, M. J., Vasudevan, A. A. J., Wang, C., Hansen, F. K., Wiek, C., Hanenberg, H., Gertzen, C. G. W., Gohlke, H., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0531-y · Cited by 77
Recent advances in class IIa histone deacetylases research
Asfaha, Y., Schrenk, C., Avelar, L. A. A., Hamacher, A., Pflieger, M., Kassack, M. U., & Kurz, T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115087 · Cited by 74
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 73
Adhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 77
Dynamic crotonylation of EB1 by TIP60 ensures accurate spindle positioning in mitosis
Song, X., Yang, F., Liu, X., Xia, P., Yin, W., Wang, Y., Wang, Y., Yuan, X., Dou, Z., Jiang, K., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00875-7 · Cited by 74
Emerging approaches for histone deacetylase inhibitor drug discovery
Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 77
Morris, M. J., & Monteggia, L. M. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.02.005 · Cited by 78
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Can changes in histone acetylation contribute to memory formation?
López‐Atalaya, J. P., & Barco, Á. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.09.003 · Cited by 79
Innovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
Simone, A. D., & Milelli, A. (2019) · ChemMedChem · doi:10.1002/cmdc.201900174 · Cited by 74
A Direct HDAC4-MAP Kinase Crosstalk Activates Muscle Atrophy Program
Choi, M.-C., Cohen, T. J., Barrientos, T., Wang, B., Li, M., Simmons, B. J., Yang, J. S., Cox, G. A., Zhao, Y., & Yao, T. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.04.025 · Cited by 72
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 69
Giorgio, E. D., Paluvai, H., Dalla, E., Ranzino, L., Renzini, A., Moresi, V., Minisini, M., Picco, R., & Brancolini, C. (2021) · Genome biology · doi:10.1186/s13059-021-02340-z · Cited by 69
Wang, Y., Abrol, R., Mak, J. Y. W., Gupta, K. D., Ramnath, D., Karunakaran, D., Fairlie, D. P., & Sweet, M. J. (2022) · FEBS Journal · doi:10.1111/febs.16437 · Cited by 67
Histone deacetylase complexes: Structure, regulation and function
Asmamaw, M. D., He, A., Zhang, L., Liu, H., & Gao, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189150 · Cited by 70
The Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 1–11
Madsen, A. S., Kristensen, H. M. E., Lanz, G., & Olsen, C. A. (2013) · ChemMedChem · doi:10.1002/cmdc.201300433 · Cited by 67
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
Targeting class I histone deacetylases in cancer therapy
Delcuve, G. P., Khan, D. H., & Davie, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.729042 · Cited by 66
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
Auzzas, L., Larsson, A., Matera, R., Baraldi, A., Deschênes-Simard, B., Giannini, G., Cabri, W., Battistuzzi, G., Gallo, G., Ciacci, A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101092u · Cited by 65
JONES, P. G., Bottomley, M. J., Carfı́, A., Cecchetti, O., Ferrigno, F., Surdo, P. L., Ontoria, J. M., Rowley, M., Scarpelli, R., Schultz‐Fademrecht, C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.026 · Cited by 64
Self-citationHistone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
Yang, C., Croteau, S., & Hardy, P. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00626-9 · Cited by 64
Uncovering Robust Delactoylase and Depyruvoylase Activities of HDAC Isoforms
Zessin, M., Meleshin, M., Praetorius, L., Sippl, W., Bařinka, C., & Schutkowski, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00863 · Cited by 66
Moresi, V., Marroncelli, N., Coletti, D., & Adamo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.01.002 · Cited by 63
Class IIa histone deacetylases: conducting development and differentiation
Martin, M., Kettmann, R., & Dequiedt, F. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082698mm · Cited by 63
Ontoria, J. M., Altamura, S., Marco, A. D., Ferrigno, F., Laufer, R., Muraglia, E., Palumbi, M. C., Rowley, M., Scarpelli, R., Schultz‐Fademrecht, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900555u · Cited by 62
Self-citationIdentification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors
Tang, G., Wong, J. C., Zhang, W., Wang, Z., Zhang, N., Peng, Z., Zhang, Z., Rong, Y., Li, S., Zhang, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008962 · Cited by 62
Kwapis, J. L., Alaghband, Y., López, A. J., White, A. O., Campbell, R. R., Dang, R., Rhee, D., Tran, A. V., Carl, A. E., Matheos, D. P., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.274 · Cited by 62
Giorgio, E. D., Clocchiatti, A., Piccinin, S., Sgorbissa, A., Viviani, G., Peruzzo, P., Romeo, S. O., Rossi, S., Tos, A. P. D., Maestro, R., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01050-13 · Cited by 63
Griffin, E. A., Melas, P. A., Zhou, R. W., Li, Y., Mercado, P., Kempadoo, K. A., Stephenson, S. I., Colnaghi, L., Taylor, K. M., Hu, M., et al. (2017) · Science Advances · doi:10.1126/sciadv.1701682 · Cited by 63
In Vivo PET Imaging of Histone Deacetylases by 18F-Suberoylanilide Hydroxamic Acid (18F-SAHA)
Hendricks, J. A., Keliher, E. J., Marinelli, B. S., Reiner, T., Weissleder, R., & Mazitschek, R. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200620f · Cited by 59
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors
Tessier, P., Smil, D. V., Wahhab, A., Leit, S. M., Rahil, J. F., Li, Z., Déziel, R., & Besterman, J. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.010 · Cited by 59
Histone deacetylases as therapeutic targets — From cancer to cardiac disease
Abend, A., & Kehat, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.003 · Cited by 58
Selective class IIa HDAC inhibitors: myth or reality
Giorgio, E. D., Gagliostro, E., & Brancolini, C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1727-8 · Cited by 62
HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation
Nebbioso, A., Dell’Aversana, C., Bugge, A. K., Sarno, R., Valente, S., Rotili, D., Manzo, F., Teti, D. V., Mandrup, S., Ciana, P., et al. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0043 · Cited by 59
Epigenetic Mechanisms in Developmental Alcohol-Induced Neurobehavioral Deficits
Basavarajappa, B. S., & Subbanna, S. (2016) · Brain Sciences · doi:10.3390/brainsci6020012 · Cited by 60
JONES, P. G., Altamura, S., Francesco, R. D., Paz, O. G., Kinzel, O. D., Mesiti, G., Monteagudo, E. S., Pescatore, G., Rowley, M., Verdirame, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800079s · Cited by 59
Self-citationMozzetta, C., Sartorelli, V., & Puri, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.007 · Cited by 64
Luckhurst, C. A., Breccia, P., Stott, A. J., Aziz, O., Birch, H. L., Bürli, R. W., Hughes, S. J., Jarvis, R. E., Lamers, M. B. A. C., Leonard, P. M., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00302 · Cited by 57
Giorgio, E. D., Dalla, E., Franforte, E., Paluvai, H., Minisini, M., Trevisanut, M., Picco, R., & Brancolini, C. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1120 · Cited by 57
Habits are negatively regulated by histone deacetylase 3 in the dorsal striatum
Malvaez, M., Greenfield, V. Y., Matheos, D. P., Angelillis, N. A., Murphy, M. D., Kennedy, P. J., Wood, M. A., & Wassum, K. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.025 · Cited by 56
Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
Han, Y., Nie, J., Wang, D. W., & Li, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.931475 · Cited by 58
Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
Sandonà, M., Cavioli, G., Renzini, A., Cedola, A., Gigli, G., Coletti, D., McKinsey, T. A., Moresi, V., & Saccone, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054306 · Cited by 58
Hudson, G. M., Watson, P. J., Fairall, L., Jamieson, A. G., & Schwabe, J. W. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.661058 · Cited by 58
Histone deacetylase signaling in cardioprotection
Lehmann, L., Worst, B. C., Stanmore, D. A., & Backs, J. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1516-9 · Cited by 57
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Classical HDACs in the regulation of neuroinflammation
Dai, Y., Wei, T.-F., Shen, Z., Bei, Y., Lin, H., & Dai, H. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105182 · Cited by 55
Linking epigenetics to lipid metabolism: Focus on histone deacetylases
Ferrari, A., Fiorino, E., Giudici, M., Gilardi, F., Galmozzi, A., Mitro, N., Cermenati, G., Godio, C., Caruso, D., Fabiani, E. D., et al. (2012) · Molecular Membrane Biology · doi:10.3109/09687688.2012.729094 · Cited by 56
Epigenetics in anoxia tolerance: a role for histone deacetylases
Krivoruchko, A., & Storey, K. B. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0479-5 · Cited by 55
Hsu, K., Liu, C., Lin, T. E., Hsieh, J.-H., Sung, T.-Y., Tseng, H.-J., Yang, J., & Huang, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-03417-1 · Cited by 54
Nebbioso, A., Pereira, R., Khanwalkar, H., Matarese, F., García‐Rodríguez, J., Miceli, M., Logie, C., Kedinger, V., Ferrara, F., Stunnenberg, H. G., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0525 · Cited by 54
Zhu, Y., Huang, M., Bushong, E. A., Phan, S., Uytiepo, M., Beutter, E., Boemer, D., Tsui, K. C., Ellisman, M. H., & Maximov, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11409-0 · Cited by 54
Stott, A. J., Maillard, M. C., Beaumont, V., Allcock, D., Aziz, O., Borchers, A. H., Blackaby, W., Breccia, P., Creighton-Gutteridge, G., Haughan, A. F., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00532 · Cited by 53
Ozcan, L., Ghorpade, D. S., Zheng, Z., de Souza, J. C., Chen, K., Bessler, M., Bagloo, M. B., Schrope, B., Pestell, R., & Tabas, I. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.006 · Cited by 55
Targeting HDAC Complexes in Asthma and COPD
Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J. (2019) · Epigenomes · doi:10.3390/epigenomes3030019 · Cited by 52
Wu, Y., Hou, F., Wang, X., Kong, Q., Han, X., & Bai, B. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00114 · Cited by 52
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies
Brindisi, M., Senger, J., Cavella, C., Grillo, A., Chemi, G., Gemma, S., Cucinella, D. M., Lamponi, S., Sarno, F., Iside, C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.069 · Cited by 54
Wen, J., Bao, Y. J., Niu, Q., Yang, J., Fan, Y., Li, J., Jing, Y., Zhao, L., & Liu, D. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.013 · Cited by 51
Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity
Godoy, L., Lucas, J. E., Bender, A., Romanick, S., & Ferguson, B. S. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600744 · Cited by 50
Metadata
- Authors
- Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., Koch, U., De Francesco, R., Steinkühler, C., & Gallinari, P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Istituto di Ricerche di Biologia Molecolare, I.R.B.M., P. Angeletti, 00040 Pomezia, Italy
- Corresponding author
- Gallinari, P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-10-30
- Volume
- 104
- Issue
- 44
- Pages
- 17335-17340
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2077257
- OpenAlex
- W2152631096
- Cited by
- 566
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 40 · 2023: 15 · 2022: 32 · 2021: 33 · 2020: 32 · 2019: 37 · 2018: 31 · 2017: 29 · 2016: 31 · 2015: 44 · 2014: 29 · 2013: 39 · 2012: 34
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- class IIa histone deacetylases, HDAC4, HDAC5, HDAC7, HDAC9, catalytic efficiency, histone deacetylase inhibitors, class I HDACs, catalytic tyrosine, enzyme evolution, substrate specificity
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Catalysis, Enzyme Activation, HeLa Cells, Histidine, Histone Deacetylases, Humans, Models, Molecular, Mutation, Substrate Specificity, Urochordata, Vertebrates, Protein Structure, Tertiary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
